Results 141 to 150 of about 15,165 (218)

Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
In a real‐world setting, 12‐month imeglimin therapy in Japanese patients with type 2 diabetes provided sustained glycemic improvements and enhanced endogenous insulin secretion. Importantly, these durable metabolic benefits were achieved without requiring an increase in overall glucose‐lowering treatment intensity.
Yohei Fujita, Shuji Suganami, Yuka Morita, Toshio Matsui, Masahisa Hata, Masahiro Hatazaki   +5 more
wiley   +1 more source

In silico prediction and structural characterization of multifunctional bioactive peptides released from olive proteins

Journal of the Science of Food and Agriculture, Volume 106, Issue 9, Page 5463-5482, July 2026.
Abstract BACKGROUND Olive (Olea europaea L.) byproducts, such as seeds and leaves, are abundant agro‐industrial residues and represent underexplored protein sources with potential health relevance. However, the repertoire of bioactive peptides that may be released from olive proteins during gastrointestinal digestion remains poorly characterized.
Teresa Gonzalez‐de la Rosa, Luna Barrera‐Chamorro, Africa Fernandez‐Prior, Elvira Marquez‐Paradas, Maria Torrecillas‐Lopez, Fernando Rivero‐Pino, Sergio Montserrat‐de la Paz   +6 more
wiley   +1 more source

Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism.

The next generation of obesity medicines harness the activity of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors (GIPR and GLP-1R), but their mechanism of action remains unclear.

core   +1 more source

Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review

Journal of Diabetes, Volume 18, Issue 7, July 2026.
RCTs of incretin‐based treatment show effective weight loss and glycemic benefit, as well as improved CV outcomes. There is, however, uncertainty as to whether the RCTs translate to real‐world outcomes. This narrative review suggests real‐world outcomes are comparable to RCTs after accounting for submaximal dosing and high discontinuation rates ...
Zachary Bloomgarden
wiley   +1 more source

Interplay of the ENS and Microbiota With Murine Gut Epithelium‐Derived Organoids in Aging

Aging Cell, Volume 25, Issue 7, July 2026.
A gut organoid model was developed to study the impact of age‐related changes of the enteric nervous system (ENS) and microbiome on the integrity and trophic capacity of the intestinal epithelial barrier. Organoids reflected in vivo aging features, including altered epithelial integrity and changes in acetylcholine‐related enzyme activity.
Tinh Thi Nguyen, Dennis Schapelhouman, Katharina Fischer, Jia‐Xuan Chen, Mario Dejung, Fridolin Kielisch, Julia Varga, Johannes Piepgras, Matthew Ahn, Oliver Tüscher, Peter Baumann, Sandra Schick, Kristina Endres   +12 more
wiley   +1 more source

Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists. [PDF]

J Diabetes Investig
Kubota S, Seino Y, Yabe D.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort

Alcohol, Clinical and Experimental Research, Volume 50, Issue 7, July 2026.
This cohort study examined whether GLP‐1 receptor agonist prescriptions are associated with alcohol use among NIH All of Us participants. Those with current GLP‐1RA prescriptions showed modestly lower AUDIT‐C scores compared to those with future prescriptions. GLP‐1RAs may reduce alcohol consumption by reducing drinking frequency.
Benjamin Tyndall, Angela Gasdaska, M. Daniel Brannock, Ed Preble, Melissa McPheeters, Laura Marcial, Ariba Huda, Josephine Egan, Tamara R. Litwin, Jennifer Adjemian, Chandan Sastry, Mehdi Farokhnia, Lorenzo Leggio   +12 more
wiley   +1 more source

The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism. [PDF]

Int J Mol Sci
Lin A, Kitaura H, Ohori F, Marahleh A, Ma J, Fan Z, Narita K, Murakami K, Kanetaka H.   +8 more
europepmc   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk. [PDF]

Eur Heart J
Emanuelsson F, Nordestgaard BG, Benn M.
europepmc   +1 more source